Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Physical Frailty Intervention for Older Adults With Hypertension and Physical Frailty (PFIM)

12 de novembro de 2026 atualizado por: Dong Yuan

Development and Evaluation of Physical Frailty Intervention Module for Older Adults With Hypertension in Shandong Province, China

Physical frailty is a common health concern among older adults with hypertension and may contribute to reduced physical function, loss of independence, and poorer quality of life. This study aims to evaluate the effectiveness of a 12-week nurse-led Physical Frailty Intervention Module (PFIM) among community-dwelling older adults with hypertension and physical frailty in Shandong Province, China.

This nonrandomized controlled study will recruit 124 participants aged 60 years or older from three primary healthcare institutions. Two institutions will be assigned to the intervention group, which will receive the PFIM in addition to usual care, while one institution will serve as the control group and provide usual care only.

The PFIM is based on the Health Action Process Approach (HAPA) and combines simplified Baduanjin exercise, basic nutrition guidance, hypertension self-management education, and behavioral support. The intervention includes nurse-led group sessions, individualized home-based exercise, and follow-up support over 12 weeks.

Physical frailty will be the primary outcome. Physical performance, nutritional status, health literacy, perceived social support, depressive symptoms, and quality of life will be assessed as secondary outcomes at baseline and after 12 weeks.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

This study is the third phase of a multiphase research project involving the development, validation, and evaluation of a Physical Frailty Intervention Module (PFIM) for older adults with hypertension and physical frailty.

A pragmatic, two-arm, nonrandomized controlled quasi-experimental design will be used. The study will be conducted at three primary healthcare institutions in Yanzhou District, Jining, Shandong Province, China. Two institutions will be allocated to the intervention group and one to the control group to minimize contamination. The planned sample size is 124 participants, with 62 participants per group.

The 12-week PFIM is informed by the Health Action Process Approach (HAPA) and delivered by trained nurses. It comprises three stages:

Weeks 1-4 focus on motivation and participation preparation through weekly face-to-face group education sessions addressing physical frailty, hypertension, nutrition, exercise safety, and behavioral change.

Weeks 5-8 emphasize action planning and behavior initiation through weekly group sessions and home-based simplified Baduanjin practice two to three times weekly for 15-20 minutes per session.

Weeks 9-12 focus on behavior maintenance through continued home practice, progressing toward 20-30 minutes per session when appropriate, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11.

Standing or seated simplified Baduanjin exercises will be assigned according to participants' physical performance and clinical safety assessments. The control group will receive usual hypertension care without the structured PFIM.

The primary outcome is physical frailty severity, measured using the FRAIL Scale. Secondary outcomes include physical performance (SPPB), nutritional status (MNA-SF), health literacy (HLS-SF12), perceived social support (PSSS), depressive symptoms (GDS-15), and quality of life (OPQOL-brief). Outcomes will be assessed at baseline and immediately after the 12-week intervention.

Tipo de estudo

Intervencional

Inscrição (Estimado)

124

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Shandong
      • Jining, Shandong, China, 272100
        • Caohe Town Health Center
        • Contato:
      • Jining, Shandong, China, 272100
        • Jiuxianqiao Subdistrict Community Health Service Center
        • Contato:
      • Jining, Shandong, China, 272100
        • Yandian Central Health Center
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

60 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Aged 60 years or older.
  • Physician-diagnosed hypertension or current use of physician-prescribed antihypertensive medication.
  • Physical frailty, defined as a FRAIL Scale score of 3 or higher.
  • Community-dwelling and residing within the catchment area of one of the participating primary healthcare institutions.
  • Adequate cognitive and communication abilities to understand study procedures, communicate in Mandarin or the local dialect, complete questionnaires with or without assistance, and provide written informed consent.
  • Medically stable and considered fit for light-to-moderate physical activity by the treating physician.

Exclusion Criteria:

  • Major acute illness requiring hospitalization within the preceding three months, such as acute myocardial infarction, acute stroke, or acute decompensated heart failure.
  • Current participation in another structured health promotion, rehabilitation, or exercise program.
  • Disabling stroke, active or advanced cancer, advanced heart failure, severe chronic obstructive pulmonary disease, or another serious medical condition that makes participation unsafe or substantially limits life expectancy.
  • Adjusted Montreal Cognitive Assessment (MoCA) score below the prespecified education-specific thresholds: <14 for illiterate participants, <15 for those with primary-school education, or <21 for those with junior-secondary education or above. One additional point is applied for fewer than 12 years of education, up to a maximum score of 30.
  • Major visual, hearing, speech, or other communication impairment that prevents meaningful participation.
  • Severe uncontrolled psychiatric disorder, major neurocognitive disorder, or end-stage disease that prevents comprehension, cooperation, or safe participation.
  • Any other condition considered medically unsuitable for participation by the treating physician.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: PFIM Intervention Group

Participants in this group will receive the 12-week nurse-led Physical Frailty Intervention Module (PFIM) in addition to usual primary healthcare for hypertension. The intervention includes simplified Baduanjin exercise, nutrition guidance, hypertension self-management education, individualized action planning, self-monitoring, and follow-up support.

The Physical Frailty Intervention Module (PFIM) is a 12-week nurse-led behavioral intervention based on the Health Action Process Approach (HAPA). During Weeks 1-4, participants attend weekly group education sessions on physical frailty, hypertension, nutrition, and exercise safety. During Weeks 5-8, participants attend weekly group sessions and begin home-based simplified Baduanjin practice 2-3 times per week for 15-20 minutes per session. During Weeks 9-12, home practice continues, progressing toward 20-30 minutes per session as tolerated, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11. Standing or seated exercises are assigned according to physical performance and safety assessments. The intervention is provided in addition to usual hypertension care.

Sem intervenção: Usual Care Control Group

Participants in the control group will receive usual primary healthcare for hypertension, including routine blood pressure monitoring, medication management, general lifestyle advice, and regular follow-up. No structured Physical Frailty Intervention Module (PFIM) will be provided during the 12-week study period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Physical Frailty Severity Measured by the FRAIL Scale
Prazo: Baseline (Week 0) and Week 12

Physical frailty will be assessed using the five-item FRAIL Scale, covering fatigue, resistance, ambulation, illnesses, and weight loss. Each item is scored 0 or 1, yielding a total score from 0 to 5. Higher scores indicate greater frailty severity. Change will be calculated as the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Physical Performance Measured by the Short Physical Performance Battery (SPPB)
Prazo: Baseline (Week 0) and Week 12

Physical performance will be assessed using the Short Physical Performance Battery (SPPB), comprising balance, 4-meter gait speed, and repeated chair stands. Each component is scored from 0 to 4, yielding a total score from 0 to 12. Higher scores indicate better physical performance. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Nutritional Status Measured by the Mini Nutritional Assessment-Short Form (MNA-SF)
Prazo: Baseline (Week 0) and Week 12

Nutritional status will be assessed using the six-item Mini Nutritional Assessment-Short Form (MNA-SF). Total scores range from 0 to 14, with higher scores indicating better nutritional status. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Health Literacy Measured by the Health Literacy Survey-Short Form 12 (HLS-SF12)
Prazo: Baseline (Week 0) and Week 12

Health literacy will be measured using the 12-item Health Literacy Survey-Short Form (HLS-SF12), covering healthcare, disease prevention, and health promotion. Responses are converted to a standardized index ranging from 0 to 50. Higher scores indicate better health literacy. Change is the Week 12 index minus the baseline index.

Baseline (Week 0) and Week 12
Change in Perceived Social Support Measured by the Perceived Social Support Scale (PSSS)
Prazo: Baseline (Week 0) and Week 12

Perceived social support will be assessed using the 12-item Perceived Social Support Scale (PSSS), covering support from family, friends, and significant others. Each item is rated from 1 to 7, giving a total score from 12 to 84. Higher scores indicate greater perceived social support. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Depressive Symptoms Measured by the 15-Item Geriatric Depression Scale (GDS-15)
Prazo: Baseline (Week 0) and Week 12

Depressive symptoms will be assessed using the 15-item Geriatric Depression Scale (GDS-15). Each item is scored 0 or 1, giving a total score from 0 to 15. Higher scores indicate more severe depressive symptoms. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Quality of Life Measured by the Brief Older People's Quality of Life Questionnaire (OPQOL-brief)
Prazo: Baseline (Week 0) and Week 12

Quality of life will be assessed using the 13-item Brief Older People's Quality of Life Questionnaire (OPQOL-brief). Items are scored on a five-point scale and coded so that higher scores indicate better quality of life. Total scores range from 13 to 65. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

20 de novembro de 2026

Conclusão Primária (Estimado)

31 de março de 2027

Conclusão do estudo (Estimado)

31 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

12 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

12 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant-level data will not be shared outside the study team due to participant privacy and confidentiality considerations.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever